Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Federal Trade Commission
Novartis
Johnson and Johnson
Fuji
Express Scripts
Argus Health
Mallinckrodt
Colorcon
UBS

Generated: August 21, 2017

DrugPatentWatch Database Preview

Par Pharm Company Profile

« Back to Dashboard

What is the competitive landscape for PAR PHARM, and when can generic versions of PAR PHARM drugs launch?

PAR PHARM has two hundred and twelve approved drugs.

There is one US patent protecting PAR PHARM drugs on PAR PHARM drugs in the past three years. There are fourteen tentative approvals on PAR PHARM drugs.

There are nine patent family members on PAR PHARM drugs in eight countries.

Summary for Applicant: Par Pharm

Patents:1
Tradenames:124
Ingredients:121
NDAs:212
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Par Pharm
METAPROTERENOL SULFATE
metaproterenol sulfate
TABLET;ORAL072025-001Jun 28, 1988RXNoYes► Subscribe► Subscribe► Subscribe
Par Pharm
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE
amitriptyline hydrochloride; perphenazine
TABLET;ORAL070595-001Sep 11, 1986DISCNNoNo► Subscribe► Subscribe► Subscribe
Par Pharm
METHYLDOPA AND CHLOROTHIAZIDE
chlorothiazide; methyldopa
TABLET;ORAL070783-001Nov 6, 1987DISCNNoNo► Subscribe► Subscribe► Subscribe
Par Pharm
DILTIAZEM HYDROCHLORIDE
diltiazem hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL074984-001Dec 20, 1999AB3RXNoNo► Subscribe► Subscribe► Subscribe
Par Pharm
IMIPRAMINE HYDROCHLORIDE
imipramine hydrochloride
TABLET;ORAL089422-001Jul 14, 1987ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Par Pharm

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Par Pharm Inc
ACCOLATE
zafirlukast
TABLET;ORAL020547-001Sep 26, 1996► Subscribe► Subscribe
Par Pharm
CAPOTEN
captopril
TABLET;ORAL018343-007Jun 13, 1995► Subscribe► Subscribe
Par Pharm
CAPOTEN
captopril
TABLET;ORAL018343-004Jun 13, 1995► Subscribe► Subscribe
Par Pharm
CAPOTEN
captopril
TABLET;ORAL018343-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Par Pharm
CAPOTEN
captopril
TABLET;ORAL018343-007Jun 13, 1995► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for PAR PHARM drugs

Drugname Dosage Strength Tradename Submissiondate
cyanocobalamin
Nasal Spray500 mcg/spray
NASCOBAL
4/28/2017
zafirlukast
Tablets10 mg and 20 mg
ACCOLATE
2/29/2008

International Patent Family for Par Pharm Drugs

Country Document Number Estimated Expiration
European Patent Office1948613► Subscribe
Canada2605413► Subscribe
Mexico2007013118► Subscribe
China101163679► Subscribe
Japan5378788► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Par Pharm Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB11/015United Kingdom► SubscribePRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
315Luxembourg► SubscribePRODUCT NAME: COMBINAISON COMPRENANT ALISKIREN,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE,ET AMLODIPINE,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE
12/033Ireland► SubscribePRODUCT NAME: TRAVOPROST (ALSO CALLED FLUPROSTENOL ISOPROPYL ESTER); NAT REGISTRATION NO/DATE: EU/1/01/199/001-002 20011129; FIRST REGISTRATION NO/DATE: EU/1/01/199/001-002 20011129; PAEDIATRIC INVESTIGATION PLAN: P/0298/2013 PROCEEDINGS UNDER SECTION 37 OF THE PATENTS ACT, 1992 RESTORATION ORDER DATED 12TH JANUARY 2016, WAS MADE RESTORING THE PATENT MENTIONED BELOW S85583 PAUL DOYLE A RE-USABLE BAG SYSTEM RESTORATION ORDERS DATED 16TH FEBRUARY 2016, WERE MADE RESTORING THE PATENTS MENTIONED BELOW S86133 MERVYN GREENE MULTI PURPOSE TANK STAND WITH COMPLEX LOCKING MECHANISM 86119 MPC GREEN LIMITED ANEW BIN
0443983/03Switzerland► SubscribePRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
C0031Belgium► SubscribePRODUCT NAME: ZAFIRLUKAST; NAT. REGISTRATION NO/DATE: 624 S 295 F 3 19961216; FIRST REGISTRATION: IE PA 51/67/1 19960103
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
US Army
Dow
Moodys
Harvard Business School
Merck
Accenture
Johnson and Johnson
Baxter
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot